The IGF2BP1 Knockout HEK293T Polyclonal Cells are a heterogeneous CRISPR/Cas9-edited population of human embryonic kidney HEK293T cells with disruption of the IGF2BP1 gene. This polyclonal knockout pool provides a rapid loss-of-function model without single-cell cloning, enabling immediate bulk functional assays. It is ideal for pooled screening, comparative phenotypic analyses, and validation of target gene dependency in cancer-relevant signaling.
HEK293T cells, derived from human embryonic kidney cells transformed with adenovirus 5 DNA, stably express SV40 large T antigen, facilitating episomal plasmid replication. This line is widely used for high-level transient protein expression and viral production due to robust growth, high transfection efficiency, and a well-characterized background suitable for gene function and signal transduction studies.
IGF2BP1 is an oncofetal RNA-binding protein that post-transcriptionally regulates target mRNAs via KH domain recognition of m6A and AU-rich elements, stabilizing transcripts including MYC, IGF2, CD44, ACTB, PTEN, and KRAS. Transcriptionally activated by MYC and ??-catenin/TCF downstream of WNT, and regulated by mTORC1, IGF2BP1 forms complexes with IGF2BP3, ELAVL1/HuR, YBX1, and FMR1 to coordinate mRNA transport and translation. Through these interactions, it integrates upstream oncogenic signals to enhance the expression of proliferation and migration factors, establishing positive feedback loops that drive tumor progression. This drives cell proliferation, migration, invasion, and EMT, making it a key oncogenic hub.
In HEK293T cells, which exhibit active WNT and mTOR signaling, IGF2BP1 knockout allows dissection of its roles in RNA regulation and oncogenic pathways. The loss of IGF2BP1 disrupts the stabilization and translation of target mRNAs like CD44 and MYC, providing a model to study RNA localization, translational control, and tumorigenic mechanisms. This system is particularly relevant for investigating IGF2BP1-driven processes in neuroblastoma, colorectal, hepatocellular, and ovarian cancers, where its overexpression is frequently observed.
Applications include functional studies of RNA-binding protein networks, CRISPR validation, and drug target discovery. This polyclonal knockout supports western blotting, RT-qPCR, RNA immunoprecipitation, RNA sequencing, immunofluorescence, and functional assays such as migration, invasion, and proliferation studies. Reporter gene assays enable pathway-specific analyses. For further information or a quote, contact Ascent Research.
